IVF Advance: New Hope for Fertility Treatment

Researchers from the Max Planck Institute, in collaboration with the start-up Ovo Labs, have identified a key factor responsible for in vitro fertilization (IVF) failures: the aging of eggs, and not female hormones as previously thought.

The study, presented at a scientific conference in Edinburgh, reveals that the decline in a protein called Shugoshin 1 plays a central role in the increase in chromosomal abnormalities seen in the eggs of older women. This protein, essential for cell division and chromosome stability, sees its production decrease with age, leading to a higher percentage of defective eggs.

By directly targeting Shugoshin 1, the researchers developed an experimental approach consisting of injecting the protein before ovarian puncture. The results are promising: the rate of oocytes with chromosomal abnormalities fell from 53% to only 29% in women who received the treatment. This significant reduction could concretely improve the chances of success of IVF cycles, thus limiting the need to repeat multiple attempts and providing a more effective solution from the first try.

For patients, this advance represents real hope. Currently, the success rate of IVF remains limited, especially among women over 35, largely due to the quality of the eggs. The potential to improve this quality through targeted intervention on Shugoshin 1 could transform the PMA experience, both medically and emotionally, by reducing the stress and costs associated with repeated cycles.

Despite these encouraging results, the researchers emphasize that the technique remains experimental. Before it can be applied on a large scale, additional clinical trials will need to be conducted to confirm its effectiveness and safety. Nevertheless, this discovery constitutes an important step towards more personalized and more effective fertility treatments, and could mark a turning point in the fight against age-related infertility.